Please ensure Javascript is enabled for purposes of website accessibility

Why NRx Pharmaceuticals Stock Is Skyrocketing Today

By Keith Speights – Oct 12, 2021 at 3:34PM

Key Points

  • NRx submitted documentation to the FDA related to the manufacturing of Zyesami.
  • The company also reported the completion of a European inspection of a manufacturing site for the drug.
  • Both developments are key steps toward completing regulatory filings for Zyesami.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced progress on two fronts for its experimental COVID-19 drug Zyesami.

What happened

Shares of NRx Pharmaceuticals (NRXP 2.78%) were skyrocketing 38.4% higher as of 3:11 p.m. EDT on Tuesday. The big jump came after the company announced two positive updates related to pipeline candidate Zyesami.

NRx said that it has submitted a revised Investigational New Drug (IND) module on the manufacturing of Zyesami to the U.S. Food and Drug Administration (FDA). This filing includes documentation confirming Nephron Pharmaceuticals is ready to supply the drug on a commercial scale. In addition, NRx stated that a European inspection at another manufacturing facility for Zyesami has been completed with "no adverse findings." 

Coronavirus image on top of an image of the Earth.

Image source: Getty Images.

So what

Both of these developments are important to NRx. They reflect progress toward critical regulatory filings for Zyesami in treating COVID-19-related respiratory failure.

NRx's revised IND module will be used by the FDA as part of its rolling review process for Zyesami. The European inspection is a key prerequisite for the company to file for approvals/authorizations of the drug by the European Union and the United Kingdom.

Now what

The really big catalyst for the biotech stock that investors anxiously await is Emergency Use Authorization (EUA) or approval for Zyesami in a major market. NRx has already won EUA for the COVID-19 drug in the nation of Georgia.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

NRx Pharmaceuticals, Inc. Stock Quote
NRx Pharmaceuticals, Inc.
$1.48 (2.78%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.